International consensus statement on allergy and rhinology: Olfaction.

BACKGROUND: The literature regarding clinical olfaction, olfactory loss, and olfactory dysfunction has expanded rapidly over the past two decades, with an exponential rise in the past year. There is substantial variability in the quality of this literature and a need to consolidate and critically review the evidence. It is with that aim that we have gathered experts from around the world to produce this International Consensus on Allergy and Rhinology: Olfaction (ICAR:O). METHODS: Using previously described methodology, specific topics were developed relating to olfaction. Each topic was assigned a literature review, evidence-based review, or evidence-based review with recommendations format as dictated by available evidence and scope within the ICAR:O document. Following iterative reviews of each topic, the ICAR:O document was integrated and reviewed by all authors for final consensus. RESULTS: The ICAR:O document reviews nearly 100 separate topics within the realm of olfaction, including diagnosis, epidemiology, disease burden, diagnosis, testing, etiology, treatment, and associated pathologies. CONCLUSION: This critical review of the existing clinical olfaction literature provides much needed insight and clarity into the evaluation, diagnosis, and treatment of patients with olfactory dysfunction, while also clearly delineating gaps in our knowledge and evidence base that we should investigate further.

Patient perspectives on recall period and response options in patient-reported outcome measures for chronic rhinosinusitis symptomatology: A pilot study.

OBJECTIVE: Patient-reported outcome measures (PROMs) for assessment of chronic rhinosinusitis (CRS) employ a variety of recall periods and response scales for reporting CRS symptom burden. CRS patient perspective is unknown with respect to recall periods and response scales in PROMs. DESIGN: Cross-sectional study. SETTING: Tertiary rhinology clinic. PARTICIPANTS: Sixty three adults with CRS. MAIN OUTCOME MEASURES: Participants were asked to choose which CRS symptom recall period-1 day, 2 weeks, 1 month or greater than 1 month-was most reflective of their current disease state and best to base treatment recommendations (including surgery) upon. Participants were also asked to report which of six response scales (one visual analogue scale [VAS] and five Likert scales ranging from four to eight items) were easiest to use and understand, and most preferred. RESULTS: A majority of participants felt the current state of their CRS symptoms was best reflected by a recall period of 2 weeks to 1 month; however, patients preferred that recommendations about treatments, including endoscopic sinus surgery, be determined by symptoms experienced over at least a one-month period. Participants generally found the VAS and seven-item Likert scale to be the easiest to use and understand, and their most preferred scales. No patient characteristics associated with preferences for recall periods or response scales. CONCLUSION: Future PROMs for CRS symptoms should consider assessment of symptoms over a one-month time frame and use either a VAS or seven-item Likert response scale to optimally balance reflection of current disease state, need for intervention and patient preference.

Clinical Consensus Statement: Septoplasty with or without Inferior Turbinate Reduction.

OBJECTIVE: To develop a clinical consensus statement on septoplasty with or without inferior turbinate reduction. METHODS: An expert panel of otolaryngologists with no relevant conflicts of interest was assembled to represent general otolaryngology and relevant subspecialty societies. A working definition of septoplasty with or without inferior turbinate reduction and the scope of pertinent otolaryngologic practice were first established. Patients 18 years and older were defined as the targeted population of interest. A modified Delphi method was then used to distill expert opinion into clinical statements that met a standardized definition of consensus. RESULTS: The group defined nasal septoplasty as a surgical procedure designed to correct a deviated nasal septum for the purpose of improving nasal function, form, or both. After 2 iterative Delphi method surveys, 20 statements met the standardized definition of consensus, while 13 statements did not. The clinical statements were grouped into 8 categories for presentation and discussion: (1) definition and diagnosis, (2) imaging studies, (3) medical management prior to septoplasty, (4) perioperative management, (5) surgical considerations, (6) adjuvant procedures, (7) postoperative care, and (8) outcomes. CONCLUSION: This clinical consensus statement was developed by and for otolaryngologists and is intended to promote appropriate and, when possible, evidence-based care for patients undergoing septoplasty with or without inferior turbinate reduction. A complete definition of septoplasty with or without inferior turbinate reduction was first developed, and additional statements were subsequently produced and evaluated addressing diagnosis, medical management prior to septoplasty, and surgical considerations, as well as the appropriate role of perioperative, postoperative, and adjuvant procedures, in addition to outcomes. Additionally, a series of clinical statements were developed, such as "Computed tomography scan may not accurately demonstrate the degree of septal deviation," "Septoplasty can assist delivery of intranasal medications to the nasal cavity," "Endoscopy can be used to improve visualization of posterior-based septal deviation during septoplasty," and "Quilting sutures can obviate the need for nasal packing after septoplasty." It is anticipated that the application of these principles will result in decreased variations in the care of septoplasty patients and an increase in the quality of care.

The utility of magnetic resonance imaging in the diagnostic evaluation of idiopathic olfactory loss.

OBJECTIVES/HYPOTHESIS: To report the utilization and cost effectiveness of magnetic resonance imaging (MRI) in the evaluation of patients with idiopathic olfactory loss. STUDY DESIGN: Case series with chart review. METHODS: A retrospective review of patients presenting with olfactory disorders at a university-based taste and smell center from July 1998 through October 2011 was performed to determine the diagnostic utility of MRI in the evaluation of patients with idiopathic olfactory loss. RESULTS: In a cohort of 839 patients with olfactory loss, idiopathic olfactory loss was most common, accounting for 247 patients-or 29% of this cohort. MRI was used in the evaluation of idiopathic olfactory loss 54.9% of the time, and abnormalities were identified in 4.6% of these patients. However, only 0.8% of these patients had olfactory loss attributable to imaging abnormalities. Therefore, the estimated cost per attributable abnormal finding was $325,000, given an average hospital charge of $2,500 per MRI. CONCLUSION: In this cohort of patients with olfactory loss, the etiology most commonly remained idiopathic. Brain MRI, though frequently performed, demonstrated a very low diagnostic yield, with a rate of abnormal findings similar to that seen in the normal population. Based on these data, the routine use of MRI in patients presenting with isolated idiopathic olfactory loss may be unwarranted. Selection bias may contribute to the low yield of MRI among this cohort; further studies are needed to characterize those patients most likely to benefit from MRI evaluation. LEVEL OF EVIDENCE: 4.

Surgical management of adult inferior turbinate hypertrophy: a systematic review of the evidence.

OBJECTIVES/HYPOTHESIS: The evidence-based medicine (EBM) schema advocates critical appraisal of the scientific literature for treatment of diseases. The objective of this review was to analyze the role of surgery for symptomatic adult inferior turbinate hypertrophy (ITH) by focusing on the following question: In adults with nasal airway obstruction (NAO) from documented ITH having failed medical therapy, does inferior turbinate surgery improve disease-specific quality of life, symptoms, and/or objective parameters with minimum 6-month follow-up?. STUDY DESIGN: Evidence-based review. METHODS: Articles for inclusion were identified by query of appropriate search terms in the PubMed database. The articles were reviewed independently by two authors and assigned an evidence level based on standard EBM guidelines. RESULTS: The search yielded 514 abstracts for review, retrieved 143 abstracts for full review, and included 96 articles in the report. The majority of the articles were assigned level 4 (75) or level 5 (18) evidence. One report was assigned level 1 and two reports were assigned level 2. Median number of patients reported was 50 (range, 1-533). Subjective assessment parameters were reported in 80 studies. Objective parameters were evaluated in 36 studies, including acoustic rhinometry or rhinomanometry (26) and mucociliary function (8). Overwhelming data supported efficacy of surgery for NAO from ITH with positive results reported in 93 studies. CONCLUSIONS: The literature provides considerable level 4 and 5 evidence for efficacy of surgery for adult symptomatic ITH. Given the paucity of level 1 and 2 data, future studies should focus on prospective studies with matched control groups for comparison.

Evidence supporting endoscopic sinus surgery in the management of adult chronic rhinosinusitis: a systematic review.

BACKGROUND: Evidence-based medicine calls for a critical evaluation of the scientific evidence for treatments of disease. This report synthesizes the available evidence on the use of endoscopic sinus surgery (ESS) in the management of adult chronic rhinosinusitis (CRS) examining the clinical question: "In adults with CRS who have failed medical management, does ESS improve symptoms and/or quality of life (QOL)?" METHODS: The American Rhinologic Society and the American Academy of Otolaryngology-Head and Neck Surgery convened a steering committee composed of the authors. Primary research articles evaluated for this report were identified using appropriate search terms and a Medline search. Two authors independently reviewed each article. Articles were assigned an evidence level based on accepted guidelines (level 1 = randomized trials; level 2 = prospective cohort studies with comparison group; level 3 = case-control studies; level 4 = retrospective case series; level 5 = expert opinion). RESULTS: We identified 886 abstracts to review, retrieved 75 articles for full review, and included 45 articles in our report. The vast majority of articles represented level 4 evidence (n = 42) and two articles represented level 5 evidence. One article was identified that qualified for level 2 evidence. All of these articles generally supported the finding that ESS improves symptoms and/or QOL in adult patients with CRS. CONCLUSION: There is substantial level 4 evidence with supporting level 2 evidence that ESS is effective in improving symptoms and/or QOL in adult patients with CRS. Future research efforts should focus on prospective studies that include appropriate comparison groups in their design.

Postviral olfactory loss.

A viral upper respiratory infection is one of the most commonly identified causes of olfactory loss, accounting for 20% to 30% of patients in most series. Given the ubiquitous nature of upper respiratory infections, it is not clear what predisposes some patients to develop this complication. Studies have demonstrated degenerative changes within the olfactory epithelium, the severity of which seems to correlate with the severity of olfactory loss. Although no available therapy has proved effective, long-term follow-up data have found that approximately two thirds of these patients eventually experience a significant improvement in their olfactory function.

The clinical effects of hyaluronic acid ester nasal dressing (Merogel) on intranasal wound healing after functional endoscopic sinus surgery.

OBJECTIVES: We sought to determine the efficacy of MeroGel, an absorbable hyaluronic acid nasal dressing (HA) in reducing synechia after functional endoscopic sinus surgery (FESS) compared with Merocel, a nonabsorbable packing (NAP) requiring removal. METHODS: We conducted a blinded, randomized, controlled trial of 37 patients requiring bilateral FESS for chronic sinusitis. Patients were randomized to placement of HA within the right or left middle meatus and NAP on the other side. Patients were evaluated at 2, 4, 6, and 8 weeks postoperatively. RESULTS: Blinded evaluation revealed 5 patients (14%) with synechia at last follow-up: 3 sides (8%) with HA and 3 (8%) with NAP. Thirteen patients (35%) had synechia at any visit, 10 sides (27%) with HA and 9 (24%) with NAP. Seven patients (19%) required lysis of synechia, 5 sides (14%) with HA and 3 (8%) with NAP. CONCLUSION: We found no statistically significant difference between HA and NAP dressings.